Meeting
2013 ASCO Annual Meeting
MEDI-551, an anti-CD19 antibody active in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab.
Authors
Mehdi Hamadani
Osborn Hematopoietic Malignancy and Transplant Program, West Virginia University, Morgantown, WV
Mehdi Hamadani , Andres Forero , Thomas J. Kipps , Michelle A. Fanale , Antonio Cuneo , Jaime Perez de Oteyza , Douglas Gladstone , Trishna Goswami , Ramy A. Ibrahim , Meina Liang , Steven Eck , Nairouz Elgeioushi , Ronald Herbst , Bruce D. Cheson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Citation
J Clin Oncol 31, 2013 (suppl; abstr 7045)
DOI
10.1200/jco.2013.31.15_suppl.7045
Abstract #
7045
Poster Bd #
35E
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL.
First Author: Douglas Edward Gladstone
Poster
2022 ASCO Annual Meeting
Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.
First Author: Wojciech Jurczak
Poster
2016 ASCO Annual Meeting
Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Jeffrey Alan Jones
Poster
2014 ASCO Annual Meeting
Treatment patterns, mortality, and costs of care in unfit patients (pts) with relapsed chronic lymphocytic leukemia (CLL).
First Author: Helen Varker